Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Raw Materials (2021 - 2026)

Organogenesis Holdings has reported Raw Materials over the past 5 years, most recently at $14.3 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 8.2% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $14.3 million, up 8.2%, while the annual FY2025 figure was $14.3 million, 8.2% up from the prior year.
  • Raw Materials for Q4 2025 was $14.3 million at Organogenesis Holdings, up from $14.1 million in the prior quarter.
  • Over five years, Raw Materials peaked at $14.3 million in Q4 2025 and troughed at $9.0 million in Q4 2021.
  • A 5-year average of $12.8 million and a median of $13.3 million in 2023 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: surged 36.12% in 2022 and later fell 6.42% in 2024.
  • Year by year, Raw Materials stood at $9.0 million in 2021, then skyrocketed by 36.12% to $12.3 million in 2022, then increased by 5.75% to $13.0 million in 2023, then rose by 2.03% to $13.3 million in 2024, then grew by 8.2% to $14.3 million in 2025.
  • Business Quant data shows Raw Materials for ORGO at $14.3 million in Q4 2025, $14.1 million in Q3 2025, and $13.9 million in Q2 2025.